Printer Friendly

NUTRAMAX TO MARKET PRIVATE LABEL O-T-C FEMININE YEAST INFECTION MEDICATION PRODUCTS

 GLOUCESTER, Mass., June 17 /PRNewswire/ -- NutraMax Products, Inc. (NASDAQ: NMPC), today announced the signing of an exclusive manufacturing and supply agreement to market over-the-counter feminine yeast infection medications to leading mass retailers for their store brand labels.
 Under the agreement, NutraMax will market products containing the active ingredient Clotrimazole in both cream and insert forms. NutraMax will be the only private label manufacturer with FDA approved-feminine yeast infection medication products in both cream and insert form. The company anticipates first shipments to customers to begin in late fall 1993.
 The retail over-the-counter market for feminine yeast infection medications is currently dominated by Monistat-7 (J&J Ortho Division) and Gyne-Lotrimin(R) (Schering-Plough). Feminine yeast infection medication products were first switched from Rx to OTC in 1991. Since going over-the-counter, these products have become widely used, as consumers turn to self-medication as a cost-saving health care alternative.
 Donald E. Lepone, president and chief executive officer of NutraMax, stated: "This agreement is consistent with our strategy of entering large and growing categories which are dominated by high-priced branded products. With over 90 percent of the private label disposable douche market, this addition to our product line will allow us to give our retail customers a full line of products in these categories."
 The agreement is for three years, subject to renewal, and gives NutraMax the right to market store brand feminine yeast infection medication products supplied by a U.S. pharmaceutical manufacturer on an exclusive basis in the United States, subject to certain minimum annual purchase requirements.
 In addition to disposable douches, NutraMax is the leading private label manufacturer and distributor of ready-to-use enemas, baby bottle liners, and pediatric electrolyte oral maintenance solutions for the store brand market.
 -0- 6/17/93
 /CONTACT: Donald E. Lepone, chief executive officer of NutraMax Products, 508-283-1800, or Lynn Morgen or Amy Weisman of Morgen-Walke, 212-850-5600, for NutraMax Products/


CO: NutraMax Products, Inc. ST: Massachusetts IN: SU:

MJ-CC -- PH022 -- 3146 06/17/93 13:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1993
Words:329
Previous Article:SUNGARD(R) DATA SYSTEMS INC. AND SUN DATA, INC. REACH AGREEMENT IN PRINCIPLE ON DISASTER RECOVERY ACQUISITION
Next Article:PENNDOT OPENS BIDS TO COMPLETE INDIANA BYPASS
Topics:


Related Articles
NUTRAMAX SIGNS AGREEMENT TO ENTER OPHTHALMICS MARKET
SCHERING-PLOUGH HEALTHCARE PRODUCTS INTRODUCES GYNE-LOTRIMIN COMBINATION-PACK FOR TREATING VAGINAL YEAST INFECTIONS
NUTRAMAX VOTED 1993 PRIVATE LABEL COMPANY OF THE YEAR
NUTRAMAX COMPLETES POWERS ACQUISITION
PERRIGO NAMES MARK OLESNAVAGE PRESIDENT OF OTC PHARMACEUTICALS
PROCTER-SYNTEX ANNOUNCES CLEARANCE OF SECOND CONSUMER BRAND
NutraMax to Repurchase 47% of its Outstanding Shares
Bristol-Myers Squibb Company Announces FDA Marketing Clearance of OTC VAGISTAT-1; First One-Dose OTC Treatment for Vaginal Yeast Infections
Bristol-Myers Squibb Company Announces Nationwide Availability of VAGISTAT-1; First One-Dose OTC Vaginal Yeast Infection Treatment
NutraMax Enters Agreement to Acquire American White Cross First Aid Business

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters